ATH — Alterity Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$42.56m
- AU$38.13m
- AU$0.27m
Annual income statement for Alterity Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.017 | 0.021 | 0.003 | 0.016 | 0.268 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 13.8 | 15.2 | 16 | 14.6 | 19.6 |
| Operating Profit | -13.8 | -15.2 | -16 | -14.6 | -19.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.5 | -15.3 | -12.8 | -13.7 | -19.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.5 | -15.3 | -12.8 | -13.8 | -19.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.5 | -15.3 | -12.8 | -13.8 | -19.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.5 | -15.3 | -12.8 | -13.8 | -19.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.015 | -0.009 | -0.005 | -0.006 | -0.005 |